Onchilles Pharma

Executive Summary

Onchilles Pharma is a preclinical-stage biotechnology company pioneering the ELANE pathway to develop next-generation pan-cancer biologics. Based in San Diego and founded in 2021, the company's platform targets a novel mechanism of action with the potential to treat multiple solid tumors, including head and neck, skin, breast, and lung cancers. Onchilles is advancing its lead program toward first-in-human clinical trials, originally planned for 2025, with IND-enabling activities ongoing. The ELANE pathway represents a differentiated approach in immuno-oncology, aiming to overcome limitations of existing therapies. However, as a private, early-stage company with no disclosed funding or valuation, Onchilles faces significant development and regulatory risks. Success will depend on preclinical validation, successful IND filing, and initial clinical data. The company's pipeline details remain undisclosed, but its focus on pan-cancer applicability and biologics platform positions it within a competitive landscape where novel mechanisms are highly sought after.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Program50% success
• Q1 2027Initiation of First-in-Human Phase 1 Trial40% success
• Q3 2026Presentation of Preclinical Data at Major Conference70% success